http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Regeneron and Alnylam Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
-
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results
-
Alnylam Pharma (ALNY) Announces Appointment of Peter Kellogg to Board of Directors
-
Alnylam Announces Appointment of Peter Kellogg to Board of Directors
-
Alnylam to Webcast Presentations at Upcoming March Investor Conferences
-
Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Period Activity
-
Alnylam Pharma (ALNY) Announces FDA Acceptance of sNDA for ONPATTRO for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
-
Alnylam Announces U.S. Food and Drug Administration (FDA) Acceptance of Supplemental New Drug Application for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
-
Alnylam to Webcast Conference Call Discussing Fourth Quarter and Full Year 2022 Financial Results
-
Alnylam Pharma (ALNY) Reports Prelim FY22 Product Revenues, Provides Additional Updates
-
Alnylam Announces Preliminary* Fourth Quarter and Full Year 2022 Global Net Product Revenues and Provides Additional Updates
-
Alnylam Pharma (ALNY) Announces Board Changes
-
Alnylam Pharma (ALNY) Announces Board Changes
-
Alnylam Announces Updates to its Board of Directors
-
Alnylam to Webcast Presentation at 41st Annual J.P. Morgan Healthcare Conference
-
Alnylam Submits CTA Application for ALN-KHK, an Investigational RNAi Therapeutic for the Treatment of Type 2 Diabetes
-
Alnylam Announces 2023 Product and Pipeline Goals and Provides Program Updates at R&D Day
-
Alnylam Pharma (ALNY) Submits sNDA to FDA for ONPATTRO for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
-
Alnylam Submits Supplemental New Drug Application (sNDA) to U.S. Food and Drug Administration (FDA) for ONPATTRO® (patisiran) for the Treatment of the Cardiomyopathy of ATTR Amyloidosis
-
Alnylam to Webcast Virtual R&D Day
-
Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2022
-
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
-
Alnylam Recognized by Science Magazine as Top Employer for Fourth Consecutive Year
-
Alnylam Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Period Activity
-
Alnylam to Webcast Conference Call Discussing Third Quarter 2022 Financial Results
-
Alnylam Pharma (ALNY) Announces FDA Approval of Supplemental New Drug Application for OXLUMO
-
Alnylam Announces FDA Approval of Supplemental New Drug Application for OXLUMO® (lumasiran) in Advanced Primary Hyperoxaluria Type 1
-
Alnylam Pharma (ALNY) Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
-
Alnylam Presents Additional Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at Heart Failure Society of America Annual Meeting
-
Alnylam Pharma (ALNY) Announces Management Appointments
-
Alnylam Announces New Management Appointments
-
Alnylam to Host Ninth Annual “RNAi Roundtable” Webcast Series
-
Regeneron (REGN) and Alnylam (ALNY) Report Strong Data from Ongoing Phase 1 Study of ALN-HSD
-
Alnylam and Regeneron Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
-
Regeneron and Alnylam Report Promising Data from Ongoing Phase 1 Study of ALN-HSD in NASH Patients and Healthy Volunteers
-
Alnylam to Present Additional Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the Heart Failure Society of America Annual Scientific Meeting
-
Alnylam Pharma (ALNY) Reports Positive APOLLO-B Phase 3 Study of Patisiran in ATTR
-
Alnylam Presents Positive Results from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
-
Alnylam to Webcast Presentation at Morgan Stanley 20th Annual Global Healthcare Conference
-
Alnylam Pharma (ALNY) Reports Positive Results from Phase 2 Study of Cemdisiran
-
Alnylam Reports Positive Results from Phase 2 Study of Investigational Cemdisiran for the Treatment of IgA Nephropathy
-
Alnylam Pharma (ALNY) Appoints Elliott Sigal to its Board
-
Alnylam Announces Appointment of Elliott Sigal, M.D., Ph.D., to Board of Directors
-
Alnylam to Present Data from the APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy at the 18th International Symposium on Amyloidosis
-
Alnylam Pharma (ALNY) Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy Met Primary Endpoint
-
Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
-
Alnylam Ranks #1 on Fast Company’s Fourth Annual List of the 100 Best Workplaces for Innovators
-
Alnylam Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Period Activity
